A substantial proportion of the worldwide liver cancer incidence is associated with chronic hepatitis B virus (HBV) infection. The therapeutic management of HBV infections is still problematic and novel antiviral strategies are urgently required. Using the peptide aptamer screening system, we aimed to isolate new molecules, which can block viral replication by interfering with capsid formation. Eight peptide aptamers were isolated from a randomized expression library, which speci®cally bound to the HBV core protein under intracellular conditions. One of them, named C1-1, eciently inhibited viral capsid formation and, consequently, HBV replication and virion production. Hence, C1-1 is a novel model compound for inhibiting HBV replication by blocking capsid formation and provides a new basis for the development of therapeutic molecules with speci®c antiviral potential against HBV infections. Oncogene (2001) 20, 6579 ± 6586.
Introduction
With over 300 000 annual deaths, liver cancer represents the fourth most common cancer death in humans (Pisani et al., 1993) . Chronic infection with hepatitis B virus (HBV), aecting over 350 million people worldwide, is associated with an 100-fold elevated risk to develop hepatocellular carcinoma (HCC) (Beasley, 1988) and it is estimated that approximately 60 ± 80% of all HCCs are linked to persistent HBV infection (Robinson, 1994; Pisani et al., 1997) . Additional severe clinical sequelae of persistent HBV infections include chronic hepatic insuciency and liver cirrhosis. Available therapies against HBV infections still have limited ecacy. Interferon a, which has been the major treatment modality for many years, induces long term suppression of viral replication in only about 30 ± 40% of selected patients (Wright and Lau, 1993) . Recently, the nucleoside analogue lamivudine has been found to suppress HBV replication in a large proportion of treated patients (Lai et al., 1998; Dienstag et al., 1999) , however, the development of lamivudine-resistant HBV mutants was observed after long term treatment (Allen et al., 1998) . Thus, new strategies are urgently required, in order to identify antiviral agents with therapeutic potential against HBV infections.
During chronic HBV infection, a covalently closed circular viral DNA (cccDNA), which is present within the host cell nucleus, serves as template for the generation of the pregenomic RNA (pgRNA) (Summers and Mason, 1982; Tuttleman et al., 1986) . In the cytoplasm, the pgRNA is packed together with the viral polymerase into capsids, formed by 180 or 240 viral core protein subunits, which assemble from preformed core dimers (Crowther et al., 1994 , Conway et al., 1997 BoÈ ttcher et al., 1998; Wynne et al., 1999) . Maturation of the viral nucleic acid takes place within the capsids and involves a reverse transcription step, eventually resulting in a non-covalently closed, partially double stranded circular DNA genome (Summers and Mason, 1982) . Subsequently, the viral capsids acquire glycoprotein envelopes by interacting with the HBV surface (S) proteins at the endoplasmatic reticulum or proximal Golgi (Roingeard et al., 1990) and leave the host cell via vesicular transport. There is evidence that chronic HBV infection is maintained, at least in part, by shunting a proportion of the newly generated cytoplasmic nucleocapsids to the nucleus where the partially double stranded viral genome is again converted into cccDNA (Tuttleman et al., 1986; Wu et al., 1990; Ganem, 1996) . Since HBV replication requires intact core particles, it is conceivable that molecules blocking viral capsid formation possess important therapeutic potential (Scaglioni et al., 1996; von WeizsaÈ cker et al., 1997) , by interfering both with the generation of infectious virions and with the replenishment of the nuclear cccDNA during chronic infection.
The peptide aptamer system is a novel genetic approach for the isolation of peptides that bind to and functionally inhibit a given target protein at the intracellular level (Colas et al., 1996; Cohen et al., 1998; Kolonin and Finley, 1998; Fabbrizio et al., 1999; Butz et al., 2000; Colas, 2000; Hoppe-Seyler and Butz, 2000) . In an attempt to isolate novel molecules with antiviral potential against HBV, we screened a randomized peptide aptamer expression library for molecules speci®cally binding to the viral core protein under intracellular conditions. We isolated eight conformationally constrained peptides, one of them eciently inhibiting viral capsid formation, DNA replication, and virion production in mammalian cells. These molecules should serve as a basis for the development of novel therapeutic agents for the treatment of HBV infections.
Results

Identification of peptide aptamers binding to the HBV core protein
In order to isolate molecules that speci®cally bind to the HBV core protein, a peptide aptamer interaction screening was performed with a yeast strain constructed to contain three dierent Gal4-dependent selectable growth markers: GAL2-ADE2, GAL1-HIS3, and SPO13-URA3 . The complete 21 kD HBV core protein fused to the Gal4-binding domain was used as bait. As prey, 20-mer peptides of randomized sequence were expressed within the active loop of the E. coli thioredoxin A (trxA) protein, which was fused to the Gal4 activation domain. Expression of peptides within scaold proteins, such as trxA, typically results in peptides with a preferred conformation (constrained peptides, CPs) which can have high binding anities to their target (Ladner, 1995) .
Two screening rounds using a total of approximately 2610 6 yeast clones led to the isolation of nine dierent transformants that exhibited growth in the absence of adenine, due to activation of the Gal4-dependent gene GAL2-ADE2. The plasmids encoding these peptide aptamers were isolated, sequenced, and the amino acid sequences of their corresponding peptide inserts are presented in Table 1 . The plasmids were retransformed into the yeast test strain and rescreened in replica platings showing that, with the exception of C2-3, eight out of nine peptide aptamers also induced the Gal4-dependent GAL1-HIS3 gene, allowing growth in the absence of histidine. These eight aptamers were considered to be true positives. Three of them, namely C1-1, C2-2, and C2-5, were also able to induce the Gal4-dependent SPO13-URA3 gene, allowing growth in the absence of uracil (Table 1) . The SPO13-promoter of this marker gene contains a negative regulatory element and is activated only by relatively strong protein-protein interactions under the conditions used (Vidal et al., 1996) , thereby indicating that these three peptide aptamers may represent relatively strong intracellular binders. Peptide aptamers which were either arbitrarily chosen from the library (CoP) or which bind to the human papillomavirus 16 (HPV16) E6 protein (E61-1) served as negative controls and did not induce growth under any of the selection conditions (Table 1 ). In order to further demonstrate the core-binding speci®city of the peptide aptamers, they were analysed for their binding to heterologous proteins. None of the core-binding aptamers bound to heterologous proteins, such as to the HPV16 E6 protein, to the retinoblastoma tumor suppressor protein, pRb, or to the Gal4-binding domain alone, in two-hybrid assays (not shown).
Inhibition of HBV capsid formation, replication and virion production
In order to investigate whether the core-binding peptide aptamers were able to interfere with HBV capsid formation, replication, and virion production in human cells, they were expressed in Huh-7 and HepG2 human hepatoma cells, along with a head-to-tail dimer of a complete HBV genome in vector pd24. Both HepG2 and Huh-7 cells serve as useful model systems to study HBV replication, since they are able to support viral replication after transient expression of cloned HBV DNA, eventually resulting in the secretion of infectious virions into the tissue culture medium (Sureau et al., 1986; Chang et al., 1987; Yaginuma et al., 1987) . In addition, a b-galactosidase reporter plasmid was introduced as an internal control to normalize for possible variations in transfection eciency.
Approximately 48 h after transfection, cells were lysed and newly formed capsids were analysed by Western blotting following non-denaturing agarose gel electrophoresis (Calvert and Summers, 1994) . As shown in Figure 1a , one peptide aptamer, namely C1-1, eciently inhibited viral capsid formation in Huh-7 cells. This eect was reproducible and not due to a nonspeci®c toxic eect since (i) b-galactosidase activities were comparable between individual transfections, (ii) immuno¯uorescence studies did not show any morphological alterations in aptamer-expressing cells, (iii) colony formation assays selecting for aptamerexpressing cells yielded comparable colony numbers for cells expressing C1-1, other core-binding aptamers, and control aptamers not targeting the HBV core protein, and (iv) HBV RNAs were properly synthesized and to the same levels in cells expressing C1-1 or control aptamer CoP (not shown). Analogous experiments performed in HepG2 cells yielded identical results. 
Subsequently, viral nucleic acids were released from the capsids in situ and analysed on ®lters using radioactively labeled HBV-DNA as a probe. As shown in Figure 1b , peptide aptamer C1-1 also strongly reduced the amount of core particle-associated HBV nucleic acids. Core-binding peptide aptamers that did not inhibit capsid formation also did not reduce the amounts of particle-associated nucleic acids when compared to controls.
Core proteins form capsids even in the absence of any other HBV gene product (Zhou and Standring, 1992) . Importantly, this process can also be eciently inhibited by C1-1, as observed after coexpressing core proteins together with peptide aptamer C1-1, but not with other peptide aptamers ( Figure 1c ). This indicates that the inhibitory eect on capsid formation is due to targeting of the viral core protein and argues against the possibility that C1-1 may interfere with other HBV gene products important for capsid formation.
Next, we investigated whether C1-1 in¯uences the core protein concentration within cells, in which HBV replication occurs from pd24. In order to be able to dierentiate between core proteins derived from complete capsids and unassembled core dimers, cell extracts were harvested 48 h after transfection and fractionated on 10 ± 60% sucrose gradients. In line with the results from the particle blot assays ( Figure  1a ), we observed a strong reduction (over 70%, as was assessed by densitometric scanning) of capsidassociated core proteins (lower gradient fractions 4 ± 6) in the presence of C1-1 when compared to control aptamer CoP (Figure 2 ). In contrast, core concentrations from dimer-derived fractions (upper gradient fractions 14 ± 17) were comparable in the presence of C1-1 and CoP. Corresponding results were obtained by analysing the eects of C1-1 on the self assembly of core proteins expressed from p21C (not shown).
In order to investigate the in¯uence of C1-1 on HBV virion production, we analysed the cell culture medium from cells cotransfected with pd24 and expression vectors for C1-1 or control peptide aptamer CoP, respectively. After mixed CsC1/sucrose centrifugation of media samples harvested 4 days after transfection, fractions of the gradient were analysed by dot blot for the presence of HBV DNA ( Figure 3a ) and HbSAg ( Figure 3b ). Complete virions are associated with HBsAg-containing fractions (Yaginuma et al., 1987; Blum et al., 1992) , which were contained in fractions 6 ± 8 ( Figure 3b ). Expression of C1-1 reproducibly resulted in a clear decrease (over 70% as estimated by Figure 1 Inhibition of HBV capsid formation by peptide aptamer C1-1. (a) Nucleocapsids were isolated from Huh-7 cells cotransfected with pd24, containing a head-to-tail dimer of the complete HBV genome, and expression vectors coding for the indicated peptide aptamers. Mock: control transfections of Huh-7 cells with pcDNA3. After non-denaturing agarose gel electrophoresis, intact nucleocapsids were transferred onto a PVDFmembrane and detected by Western blot with an anti-HBV-core antibody. (b) Core particles were lysed in situ and the presence of core particle-associated nucleic acids was examined using radioactively labeled HBV DNA as hybridization probe. (c) Nucleocapsids from Huh-7 cells cotransfected with plasmid p21C, coding for the HBV core protein alone, and expression vectors for peptide aptamers CoP, C1-1, C1-2, and C2-2. Analysed as outlined in (a) Figure 2 Sedimentation analysis of core particles from Huh-7 hepatoma cells cotransfected with pd24 and expression vectors for CoP (upper panel) or C1-1 (lower panel), respectively. Eighteen fractions of a 10 ± 60% sucrose gradient were collected from the bottom of the tube and analysed by SDS ± PAGE and Western blot. Bottom and top of the gradients are indicated, individual gradient fractions are numbered below each panel. Note the reduction of particle-associated core protein (lower gradient fractions 4 ± 6) in the presence of C1-1 densitometric scanning) of HBsAg-associated viral DNA (Figure 3a , fractions 6 ± 7) when compared to control aptamer CoP, indicating that C1-1 also signi®cantly reduced the amount of secreted virions. In contrast, the overall HbSAg concentration in the medium was comparable for C1-1 and CoP expressing cells, further supporting the notion that C1-1 speci®-cally interferes with the formation of complete virions.
Analysis of peptide aptamer-core interactions
In order to study the interaction between peptide aptamers and the core protein in more detail, their binding to various deletion mutants of the core protein was analysed. Structurally, the full-length 183 amino acid (aa) core protein can be subdivided into assembly domains residing approximately within the N-terminal aa 1 ± 144 and a basic C-terminal region involved in nucleic-acid binding. We found that all peptide aptamers isolated bound to a truncated core protein comprising the N-terminal aa-residues 1 ± 149, in twohybrid assays (Figure 4) . Peptide aptamers C1-1 and C2-2 were no longer able to detectably interact with a core mutant exhibiting a further C-terminal deletion to aa 124 (Figure 4) , indicating that the region between aa 125 ± 149 of the HBV core protein is required for their binding. In contrast, peptide aptamer C2-5, and to some extent C1-3, C2-1, C2-4, and C2-6, bound to this mutant, but binding was completely abolished after further truncation to aa 1 ± 117. Yet another binding pattern was exhibited by C1-2 which, alike full length core protein serving as a positive control, was able to clearly interact with this latter mutant (Figure 4) . Taken together, these results indicate that the peptide aptamers bind to dierent regions of the core protein, in line with the observation that peptide aptamers can speci®cally interact with dierent faces of their target molecules (Cohen et al., 1998) .
Notably, only one out of the eight peptide aptamers that bound to the core protein in yeast, namely C1-1, eciently blocked viral capsid formation in human cells. This could be due to inecient targeting of the core protein by the non-inhibitory aptamers in mammalian cells. We therefore studied the potential of individual peptide aptamers to bind to the core protein directly in human cells (Figure 5a) . A Gal4BD-core fusion protein was coexpressed with individual peptide aptamers linked to the activation domain of the herpes simplex virus-1 VP16 protein in Huh-7 cells. In this setting, the activation of the cotransfected luciferase reporter construct is dependent on the interaction of the Gal4-Core and aptamer-VP16 fusion proteins. Interestingly, among all peptide aptamers binding to the core protein in yeast, only C1-1 was able to clearly activate the luciferase reporter in Huh-7 cells (Figure 5a and not shown). This correlated well with its ability to inhibit viral capsid formation and replication in these cells.
In order to get additional biochemical evidence that C1-1 interacts with the HBV core protein, coimmunoprecipitation analyses were performed. We co-expressed the native HBV core protein together with peptide aptamer C1-1 or control aptamer CoP, respectively, in human cells. Using antibodies against the His-tag or the thioredoxin portion of the aptamer, HBV core protein was co-immunoprecipitated with C1-1, but not with control peptide aptamer CoP (Figure  5b ), under conditions where both peptide aptamers were expressed at comparable levels ( Figure 5c ). This further supports the notion that C1-1 interacts speci®cally with the HBV core protein in mammalian cells.
Discussion
The severe clinical sequelae of chronic HBV infections and the problems associated with current treatment regimens emphasize the necessity to develop new strategies to identify molecules with antiviral activity.
In previous studies investigating the possibility of targeting HBV replication at the protein level, it has been found that slightly truncated core proteins linked to heterologous proteins, such as to the HBsAg, can act as transdominant negative inhibitors of capsid formation, packaging, and/or viral DNA synthesis (Scaglioni et al., 1994 (Scaglioni et al., , 1996 von WeizsaÈ cker et al., 1996 von WeizsaÈ cker et al., , 1998 . However, the large size and the complexity of these dominant-negative core fusion proteins restrict the possibility to determine their bioactive structure and hence, their potential to serve as lead compounds for the development of non-peptide mimetics. Attempts to further truncate the HBV core fusion proteins resulted in instability of the molecules (Scaglioni et al., 1994; von WeizsaÈ cker et al., 1996) .
Previously, a peptide could be identi®ed, by phage display, which bound to the HBV core protein (Dyson and Murray, 1995) . It interfered with the interaction between the core and the HBV long surface antigen (LHBsAg) during envelopment of the capsid (BoÈ ttcher et al., 1998). However, blocking core/L-HBsAg-interactions can prevent production of complete viral particles, but not of viral capsids. Therefore, therapeutic compounds derived from this peptide most likely would not interfere with the replenishment of the cccDNA within the chronically infected host cell, if this process is linked to shunting capsids with the newly replicated viral DNA back to the nucleus (Tuttleman et al., 1986; Wu et al., 1990; Ganem, 1996) . Indeed, interfering with the core/L-HBsAg interaction during viral assembly may even result in an increased accumulation of the viral cccDNA in the nucleus . It is therefore important to note that peptide aptamer C1-1, which we identi®ed here, acts on a dierent level to inhibit HBV replication, namely by inhibiting viral capsid formation. Hence, C1-1 should interfere both with the production of virions and with the replenishment of the cccDNA maintaining chronic HBV infection.
It is worth noting that, in contrast to C1-1, seven other peptide aptamers binding to the HBV core protein in yeast did not inhibit viral capsid formation in human cells despite the fact that they were expressed at comparable levels (not shown). A possible explanation for this observation may be found in low binding anities of the inactive peptide aptamers for the core protein in mammalian cells. Indeed, only the bioactive peptide C1-1 scored positive in a two-hybrid assay in Huh-7 cells. Such discrepancies between two-hybrid assays in yeast (using selectable growth markers) and human cells (using reporter genes) may be due to a lower sensitivity of the mammalian assay and has also been observed in a recent study analysing the binding of intracellular antibodies to their targets (Visintin et al., 1999) . Yet, therapeutic potential may also reside in low anity peptide aptamers, since anity maturation (Cunningham and Wells, 1997) by randomized mutagenesis may result in increased binding strength and convert some of them into dominant inhibitors.
Our investigations with mutant core proteins indicate that the region between amino-acids 125 ± 149 is required for binding of C1-1. This region is exposed to the outside of the core protein (Wynne et al., 1999) and has been shown to be important for the assembly of pre-formed core dimers into core particles (KoÈ nig et al., 1998) . More work is required to investigate whether this region is directly contacted by C1-1 and suces for binding, and whether the binding of C1-1 aects core dimerization and/or multimerization. Binding of C1-1 was speci®c to human hepatitis virus, in that no interaction was observed with the core protein of the duck hepatitis (DHBV), nor did C1-1 inhibit DHBV capsid formation (not shown).
The formation of HBV capsids is a concentrationdependent process, in which core dimers accumulate to a constant threshold level, and only the fraction of dimers exceeding this threshold will assemble into capsids (Zhou and Standring, 1992; Seifer and Standring, 1995) . This assembly pathway could provide an explanation, at the molecular level, for the observation that the inhibition of capsid formation by C1-1 was linked to a decrease of the overall core protein concentration, whereas the dimer fraction was comparable to that of the controls. Core dimers and complete capsids represent the only stable and detectable forms of core protein during assembly and the interference with proper assembly (i.e. with dimerization and/or multimerization) is therefore likely not only to result in a reduction of capsids, but also of the total core protein concentration. Yet, as long as there are still capsids formed, the concentration of core dimers will stay constant since it re¯ects the threshold level, above which assembly takes place. In line with this model, it has been found that varying concentrations of dimerization-competent core protein were re¯ected in changes of capsid concentrations, whereas the dimer fraction remained constant (Seifer and Standring, 1995) . A series of additional control experiments were performed to corroborate the notion that inhibition of capsid formation by C1-1 was due to speci®c targeting of the core protein. Clearly, C1-1 did not reduce capsid formation through interference with HBV gene expression, since the viral mRNAs were properly synthesized at normal levels, and inhibition of capsid formation was promoter-independent. In addition, C1-1 also inhibited the self-assembly of core protein, excluding the formal possibility that C1-1 may interfere with other HBV gene products important for capsid formation. Moreover, there was no evidence for non-speci®c cytotoxic eects associated with C1-1 expression, neither morphologically, nor in reporter gene studies, nor in colony formation assays. As a further internal control, HbSAg secretion from cells, transfected with HBV genomes, was not aected by C1-1 under conditions where capsid formation was strongly reduced.
Several aspects prompted us to use the peptide aptamer system as a screening method for the identi®cation of core-targeting peptides. First, as mentioned above, truncations of the core protein have been found to result in signi®cant instability. Therefore, it may be dicult to delineate a small, corederived inhibitory peptide by deletion mutation of the core protein. In addition, the use of a randomized peptide expression library should increase the pool of possible core binding molecules. Indeed, the inhibitor of capsid formation isolated here, C1-1, does not reveal more than random sequence similarities to the HBV core protein. Second, in view of the anticipated intracellular inhibition of a given target protein, it is advantageous that the peptide aptamer system selects for molecules which bind to their target, and are stable, under intracellular conditions. Third, the peptides analysed here are presented as constrained peptides (CPs), which, in contrast to¯exible peptides, typically possess a preferred conformation (Ladner, 1995) . This, together with their small size and the fact that the structure of the TrxA scaold is known, should help the elucidation of their bioactive structures as a prerequisite to develop non-peptide mimetics (Ladner, 1995) .
Apart from the potential to employ the coding sequences of speci®c inhibitors, such as C1-1, in gene therapy approaches to block HBV replication, the core-targeting aptamers thus open new possibilities for drug design. The principal feasibility to develop smallmolecule drugs starting from a protein structure has been demonstrated recently, most notably by the development of HIV-protease inhibitors (Leung et al., 2000) . By interfering with HBV replication at the level of capsid formation, C1-1 represents a novel model compound for the design of therapeutic agents against HBV infections. Moreover, the experimental approach to isolate inhibitory peptide aptamers that interfere with essential structural requirements of a virus should be broadly applicable and also useful for the generation of novel antiviral compounds against other viruses.
Materials and methods
Peptide aptamer screening
As bait, the full-length HBV (serotype ayw) core protein was expressed after fusing its coding sequence to the Gal4 DNAbinding domain (Gal4BD), into vector pPC97 (Chevray and Nathans, 1992) , resulting in plasmid pPC97/Core. For expression of the prey, vector pADtrx , in which the ADH1 promoter activates expression of the E. coli thioredoxin A (trxA) gene fused to the Gal4 activation domain (Gal4AD), was constructed from pRS424 (Christianson et al., 1992) . A peptide library, encoding 20-mers of randomized sequence, was expressed as prey from pADtrx in yeast test strain KF-1 , together with pPC97/Core. Following selection for growth on adeninede®cient medium (activation of GAL2-ADE2), positive clones were analysed for their ability to also induce the GAL1-HIS3, and SPO13-URA3 markers . For the analysis of binding speci®city, HPV16 E6 and pRb were expressed from pPC97. Negative control peptide aptamer CoP was arbitrarily chosen from the expression library and E61-1 was selected for binding to the HPV16 E6 protein (for sequences, please refer to Table 1 ).
Yeast and mammalian two-hybrid analyses
In order to map the core regions required for aptamer binding, deletion mutants of the core protein (aa 1 ± 149, 1 ± 124, and 1 ± 117) were generated by PCR and linked to the Gal4BD in pPC97. These mutants, as well as pPC97/Core, were expressed in KF-1, together with individual peptide aptamers generated from pADtrx, and selected for activation of the ADE2 marker. In order to analyse the aptamer/core interactions in human cells, the`CheckMate TM Mammalian Two-Hybrid System' (Promega, Mannheim, Germany) was employed. The complete HBV core protein was expressed as a Gal4BD fusion protein from pBIND. Individual peptide aptamers were expressed within the trxA scaold, linked to the transcriptional activation domain of the herpes simplex virus-1 VP16 protein, from pACT. Reporter plasmid pG5luc contains the ®re¯y luciferase gene under the transcriptional control of ®ve Gal4-binding sites. Cells were harvested 24 h after transfection, and luciferase activities were measured as described (Butz et al., 1995) .
Analysis of HBV replication, capsid formation, and virion production. Immunoprecipitation analyses Vector pd24 contains a dimer of two complete 3.2 kb unit length HBV genomes (serotype ayw) with a pre-C-mutation in codon 28, to increase replication competence, and is identical to plasmid pd2TAG-28 (Lamberts et al., 1993) . The mammalian expression vector p21C contains the complete HBV core gene and in pcDNA3 (Invitrogen, Groningen, The Netherlands). Exponentially growing Huh-7 or HepG2 cells were transfected in 6 cm Petri dishes with 3 mg of either pd24 or p21C, together with 1 mg of the CMV-promoter-driven expression vector pRc/CMV (Invitrogen, Groningen, The Netherlands) expressing individual peptides in the context of the trxA scaold. The trxA scaold was linked 3' to the HSV VP22 gene and 5' to a 6xHis-tag. This combination was chosen since VP22 localizes the peptide aptamer to the cytoplasm of human cells and may also allow intercellular spreading of the aptamers in future in vivo applications (Elliott and O'Hare, 1999) . In addition, 0.5 mg of the bgalactosidase construct pCMVGal was added, serving as internal control to account for possible variations in the transfection eciency.
Analysis for nucleocapsid particles was performed essentially as described (Calvert and Summers, 1994) . Cells were harvested 48 h after transfection in lysis buer (50 mM Tris pH 8.0, 1 mM EDTA, 1% NP40) for 5 min at 378C. The lysate was centrifuged and, after adjustment of transfection eciencies through the determination of b-galactosidase activities, the supernatant was analysed on a non-denaturing 1% agarose gel in 10 mM sodium phosphate buer (pH 7.5). Core particles were transferred onto a PVDF membrane (Polyscreen, NEN, KoÈ ln, Germany) and detected by enhanced chemiluminescence (ECL, Amersham-Pharmacia, Freiburg, Germany), using a rabbit anti-core antibody (Dako, Hamburg, Germany). Core particle-associated viral nucleic acids were released from the core particles in situ as described (Calvert and Summers, 1994) and hybridized with radioactively labeled full length HBV DNA.
In order to dierentiate between unassembled and assembled core dimers, cells were transfected on a 10 cm petri dish with 10 mg of either pd24 or p21C, and 3 mg of the respective aptamer expression vector. After 48 h, cells were lysed in 1 ml 150 mM NaCl, 50 mM Tris pH 7.5, 5 mM EDTA and 1% NP40, and the lysate was loaded onto a 10 ± 60% (wt/v) sucrose gradient in TNE (10 mM Tris pH 7.3, 100 mM NaCl, 1 mM EDTA; each step 1.8 ml). Following centrifugation at 30 000 r.p.m. for 17 h at 48C in an SW40 rotor (Beckmann Coulter, MuÈ nchen, Germany), 18 fractions of approximately 600 ml were collected from the bottom of the tube. Individual fractions were separated by 15% SDS ± PAGE and analysed by Western blot using the rabbit anticore antibody H801 (gift of H Schaller, Heidelberg). Unassembled core dimers typically mapped to fractions 14 ± 17 and capsids typically mapped to fractions 4 ± 6.
For detection of secreted HBV virions, 2.5 ml of the cell culture medium was removed 4 days after transfection and loaded onto a CsCl/sucrose gradient, consisting (from bottom to top) of three layers of 0.5 ml CsCl with refractive indexes of 1.2, 1.3, and 1.4, respectively, and one layer of 0.5 ml 20% sucrose. After centrifugation at 49 000 r.p.m. for 5 h at 208C in an AH 650 rotor (Kendro, Hanau, Germany), 12 fractions of approximately 200 ml each were collected from the bottom of the tube using the Beckman Fraction Recovery System (Beckmann Coulter). Individual fractions were tested for the presence of HBV DNA by dot blot analysis. In addition, individual fractions were tested for the presence of HBsAg by immunodotblot, using the rabbit anti-HBsAg-antibody HupreS1+2 (gift of S Urban, Heidelberg). As indicated by the concomitant presence of HBsAg and HBV DNA, complete virions typically were contained in fractions 6 and 7 of the mixed sucrose/CsCl gradient.
For immunoprecipitations, HeLa cells were transfected on a 10 cm Petri dish with 10 mg p21C and 10 mg of the respective aptamer expression vector. Cells were lysed 24 h after transfection in 1 ml 150 mM NaCl, 50 mM Tris pH 7.5, 5 mM EDTA and 0.2% NP40. Immunoprecipitations (Harlow and Lane, 1999) were performed with either an anti-His antibody (gift of H Zentgraf, Heidelberg) or an anti-thioredoxin-antibody (Invitrogen). HBV core protein binding the peptide aptamers was detected by SDS ± PAGE and Western blot of the samples using rabbit anti-core antibody H801, as described above.
